Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD  |  Issue: February 2021  |  February 16, 2021

Figure 1A

Figure 1A

Figure 1B

Figure 1B

Figure 1C

Figure 1C

Figure 1D

Figure 1D

The patient presented with periorbital edema, erythematous conjunctiva, papular lesions all over her body and a mucosal ulceration on the hard palate of her oral cavity.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A biopsy of the buccal mucosa revealed stratified squamous epithelium and underlying subepithelial connective tissue with marked acute and chronic inflammation, ulceration and necrosis. 

Stains for cytomegalovirus and herpes simplex virus were negative, and GMS and gram stains were negative for fungal elements and pathogenic bacteria. Mild perivascular inflammation was noted, but overt vasculitis was not seen. Features of Stevens-Johnson syndrome were also absent.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The renal biopsy revealed diffuse mesangial matrix expansion consistent with diabetic glomerulosclerosis class IIb (without nodular glomerulosclerosis) and very focal acute segmental necrotizing glomerulonephritis affecting 1 of 70 glomeruli in paraffin sections. 

Immunofluorescence stains were negative for IgG, IgA, kappa light chain, lambda light chain, C3 and C1q. Weak mesangial deposition of IgM was noted. Mild tubular epithelial injury was present, and there were focal red blood cell casts. Approximately 12% of glomeruli were global sclerotic (12/99 glomeruli in the specimen), and there was 10% interstitial fibrosis with tubular atrophy. 

Overall, the renal biopsy was consistent with ANCA-associated vasculitis given the presence of MPO-ANCA and the findings of pauci-immune complex deposition. However, the presence of serum anti-histone antibodies was consistent with drug-induced lupus. 

The patient was treated with 1,000 mg of intravenous methylprednisolone daily for five days, then switched to 60 mg of prednisone daily and tapered thereafter. With this treatment, her hematuria and proteinuria considerably improved, and her C3 and C4 levels normalized. 

Although hydralazine was discontinued, the patient’s condition remained active on a tapered dose of steroids. At that time, the patient was started on 375 mg/m2 rituximab weekly for four doses. Following this additional immunosuppression, her renal function normalized and her anemia resolved.

Figure 2A

1A: Glomerulus with moderate global mesangial matrix expansion consistent with moderately advanced diabetic nephropathy (without nodular glomerulosclerosis) is noted.

Figure 2B

1B: Focal glomerulus with segmental fibrinoid necrosis with extracapillary proliferation and red blood cells casts consistent with necrotizing, pauci-immune, ANCA-associated glomerulonephritis are noted. Bar=20 μm.

Conclusion 

Hydralazine is a common medication for congestive heart failure and hyper­tension that has been associated with systemic autoimmune conditions including drug-induced lupus, ANCA-associated vasculitis and leukocytoclastic vasculitis. It is thought that hydralazine accumulates in the intra­cytoplasmic neutrophilic granules, which in turn, leads to binding of myeloperoxidase and ultimately causes release of cytotoxic products and cell death. Once these neutro­phils undergo cell death, antigens that are normally sequestered are exposed. This exposure leads to uptake by antigen-presenting cells, leading to production of ANCA.2,3

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ANCA-Associated Vasculitiscase reporthydralazine

Related Articles

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Top Research in ANCA-Associated Vasculitis Presented at ACR Convergence 2023

    November 21, 2023

    SAN DIEGO—Vasculitis expert and former editor of The Rheumatologist, Dr. Philip Seo gives us his picks for the 10 most important abstracts in ANCA-associated vasculitis to come out of ACR Convergence 2023.

    Case Report: Drug-Induced Lupus

    September 14, 2021

    The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences